Lodoxamide (Lodoxamidum) is an antiallergic drug acting as a mast-cell stabilizer. It is effective in the treatment of asthma and allergic conjunctivitis.

Lodoxamide effectively inhibits histamine release induced by compound 48/80 and reduces 45Ca influx triggered by ionophores, accompanied by a decrease in histamine release in purified rat peritoneal mast cells [1]. Moreover, it significantly and dose-dependently suppresses eosinophil chemotaxis towards fMLP and IL-5. Additionally, Lodoxamide robustly inhibits the release of eosinophil peroxidase following IgA-dependent activation and, to a lesser extent, the release of eosinophil cationic protein and eosinophil-derived neurotoxin [2].

Lodoxamide has been demonstrated to have cromolyn-like activity when studied in the rat peritoneal mast cell assay (PCA) model and in Ascaris antigen-sensitized rhesus monkeys. When given intravenously, orally, or intrabronchially by aerosol, lodoxamide significantly inhibits the increased respiratory frequency and decreased tidal volume induced by antigen challenge in Ascaris-sensitized. anaesthetized rhesus monkeys [1]. Addition of lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution results in a marked decrease in lung reperfusion injury as demonstrated by increased oxygenation decreased microvascular permeability, and increased compliance [3].